Clinical trial of bovhyaluronidase azoximer raises hopes for patients with pulmonary sequelae of COVID-19
- A recent clinical trial focusing on bovhyaluronidase azoximer (BA) has yielded promising results as a potential treatment for long COVID pulmonary sequelae.
- The possible benefits of BA include improving patients’ pulmonary functions and exercise tolerance.
[The content of this article has been produced by our advertising partner.]
According to the World Health Organization (WHO), long COVID is a multisystem condition that develops in 10 to 20 percent of COVID-19 patients. Its symptoms include fatigue, breathlessness, and exercise intolerance.
One of the long COVID manifestations, known as pulmonary sequelae, includes restrictive lung disease, respiratory symptoms, and radiological abnormalities in the lungs that resemble pulmonary fibrosis. Pulmonary sequelae of COVID-19 can last for months and even years.
So far, WHO has not issued any clinical treatment guidelines for post-COVID pulmonary sequelae.
Nevertheless, hopes have been raised by the findings of a recent study. Titled “Bovhyaluronidase azoximer for long-term pulmonary sequelae of COVID-19: a randomised, double-blind, placebo-controlled trial,” the clinical trial concludes with findings that suggest a valuable direction for further investigation of BA in the treatment of pulmonary sequelae and potentially long COVID in general.
Hyaluronic acid (HA) is involved in the pathology of pulmonary sequelae. BA, a polymer-conjugated hyaluronidase, is the enzyme that catalyses the degradation of HA.
